<code id='FBCCC18062'></code><style id='FBCCC18062'></style>
    • <acronym id='FBCCC18062'></acronym>
      <center id='FBCCC18062'><center id='FBCCC18062'><tfoot id='FBCCC18062'></tfoot></center><abbr id='FBCCC18062'><dir id='FBCCC18062'><tfoot id='FBCCC18062'></tfoot><noframes id='FBCCC18062'>

    • <optgroup id='FBCCC18062'><strike id='FBCCC18062'><sup id='FBCCC18062'></sup></strike><code id='FBCCC18062'></code></optgroup>
        1. <b id='FBCCC18062'><label id='FBCCC18062'><select id='FBCCC18062'><dt id='FBCCC18062'><span id='FBCCC18062'></span></dt></select></label></b><u id='FBCCC18062'></u>
          <i id='FBCCC18062'><strike id='FBCCC18062'><tt id='FBCCC18062'><pre id='FBCCC18062'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:882
          foreign-trained health professionals
          Adobe

          The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

          The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

          advertisement

          The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          FDA approves updated Covid vaccines
          FDA approves updated Covid vaccines

          ASafewaypharmacistadministersaPfizerCovid-19boosteratavaccinationclinicinOctober2021inSanRafael,Cali

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Case highlights the risks of experimental stem cell therapy

          Neurons(red)andastrocytes(green)derivedfromhumanneuralstemcellsgrowinginculture.StevenPollard/Wellco